Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record.

A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon

Open access
Verhoef, Talitha I., Ragia, Georgia, de Boer, Anthonius, Barallon, Rita, Kolovou, Genovefa, Kolovou, Vana, Konstantinides, Stavros, Le Cessie, Saskia, Maltezos, Efstratios, van der Meer, Felix J.M., Redekop, William K., Remkes, Mary, Rosendaal, Frits R., van Schie, Rianne M.F., Tavridou, Anna, Tziakas, Dimitrios, Wadelius, Mia, Manolopoulos, Vangelis G., Maitland-van der Zee, Anke H.·2013·New England Journal of Medicine

Abstract

BACKGROUND: Observational evidence suggests that the use of a genotype-guided dosing algorithm may increase the effectiveness and safety of acenocoumarol and phenprocoumon therapy. METHODS: We conducted two single-blind, randomized trials comparing a genotype-guided dosing algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1 with a dosing algorithm that included only clinical variables, for the initiation of acenocoumarol or phenprocoumon treatment in patients with atrial fibrillation or venous thromboembolism. The primary outcome was the percentage of time in the target range for the international normalized ratio (INR; target range, 2.0 to 3.0) in the 12-week period after the initiation of therapy. Owing to low enrollment, the two trials were combined for analysis. The primary outcome was assessed in patients who remained in the trial for at least 10 weeks. RESULTS: A total of 548 patients were enrolled (273 patients in the genotype-guided group and 275 in the control group). The follow-up was at least 10 weeks for 239 patients in the genotype-guided group and 245 in the control group. The percentage of time in the therapeutic INR range was 61.6% for patients receiving genotype-guided dosing and 60.2% for those receiving clinically guided dosing (P=0.52). There were no significant differences between the two groups for several secondary outcomes. The percentage of time in the therapeutic range during the first 4 weeks after the initiation of treatment in the two groups was 52.8% and 47.5% (P=0.02), respectively. There were no significant differences with respect to the incidence of bleeding or thromboembolic events. CONCLUSIONS: Genotype-guided dosing of acenocoumarol or phenprocoumon did not improve the percentage of time in the therapeutic INR range during the 12 weeks after the initiation of therapy. (Funded by the European Commission Seventh Framework Programme and others; EU-PACT ClinicalTrials.gov numbers, NCT01119261 and NCT01119274.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1311388

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 226

Metadata

Authors
Verhoef, T. I., Ragia, G., de Boer, A., Barallon, R., Kolovou, G., Kolovou, V., Konstantinides, S., Le Cessie, S., Maltezos, E., van der Meer, F. J. M., Redekop, W. K., Remkes, M., Rosendaal, F. R., van Schie, R. M. F., Tavridou, A., Tziakas, D., Wadelius, M., Manolopoulos, V. G., & Maitland-van der Zee, A. H.
Venue
New England Journal of Medicine
Published
2013-12-12
Volume
369
Issue
24
Pages
2304-2312
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1976568296
Cited by
226
References
0
FWCI
40.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. https://app.cochat.ai/papers/10.1056/nejmoa1311388
The paper
Verhoef, T. I., Ragia, G., de Boer, A., Barallon, R., Kolovou, G., Kolovou, V., Konstantinides, S., Le Cessie, S., Maltezos, E., van der Meer, F. J. M., Redekop, W. K., Remkes, M., Rosendaal, F. R., van Schie, R. M. F., Tavridou, A., Tziakas, D., Wadelius, M., Manolopoulos, V. G., & Maitland-van der Zee, A. H. (2013). A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1311388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.